# Chronic lymphocytic leukaemia, first treatment

Source: https://onco.cc/cancers/cll-treatment-naive/  
OnCo record `cll-treatment-naive` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course.

## Summary

Diagnosis needs 5 x 10^9/L clonal B cells with the typical CD5, CD19, CD23 phenotype; treatment starts only for iwCLL indications (symptoms, progressive anaemia or thrombocytopenia, bulky or fast-growing disease), because early treatment, even with ibrutinib in CLL12, has not lengthened life. Before the first treatment, every patient has FISH and sequencing for del(17p) and TP53 mutation and testing of IGHV mutational status, since these decide the regimen: TP53-aberrant disease does not respond durably to chemotherapy, and unmutated IGHV disease relapses early after it.

Two families of drugs replaced chemoimmunotherapy between 2014 and 2023. Continuous BTK inhibitors, ibrutinib and then the better-tolerated acalabrutinib (ELEVATE-TN, versus chlorambucil-obinutuzumab: median progression-free survival not reached at six years against 27.8 months) and zanubrutinib (SEQUOIA, versus bendamustine-rituximab, hazard ratio 0.42), control the disease for years but must be taken indefinitely and carry atrial fibrillation, bleeding and hypertension risks. Fixed-duration venetoclax with obinutuzumab for 12 months (CLL14, versus chlorambucil-obinutuzumab in older unfit patients: six-year progression-free survival 53.1 percent versus 21.7 percent, hazard ratio 0.40) gives most patients undetectable MRD and years off treatment; CLL13/GAIA confirmed the same in fit patients, where venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib beat fludarabine-based chemoimmunotherapy (five-year progression-free survival 69.8 and 81.3 percent against 50.7 percent).

The third option is an all-oral fixed-duration doublet: ibrutinib-venetoclax (GLOW in older patients, hazard ratio 0.216 for progression; CAPTIVATE; and the UK FLAIR trial with MRD-guided duration) and acalabrutinib-venetoclax with or without obinutuzumab (AMPLIFY, 2025), which in 2026 joined the approved first-line options. Choice now turns on comorbidity, TP53 status (continuous BTK inhibitor favoured), patient preference for a finite course, drug interactions and cost; non-covalent BTK inhibitors, BTK degraders, sonrotoclax and MRD-guided stopping are in first-line trials.

## Fields

- Kind: Cancer
- Last checked: 2026-09-17
- Also known as: Treatment-naive CLL; Front-line CLL; Previously untreated CLL; First-line CLL therapy
- Tags: subtype-page
- Group: haematologic
- Burden: Chronic lymphocytic leukaemia is the commonest adult leukaemia in Western countries, with a median age at diagnosis of about 70; a third of patients never need treatment, and the rest start it when the disease causes symptoms, cytopenias or bulky nodes.
- Subtypes: Treatment-naive CLL without del(17p) or TP53 mutation, IGHV mutated; Treatment-naive CLL, IGHV unmutated; Treatment-naive CLL with del(17p) or TP53 mutation (continuous BTK inhibitor favoured); Older or unfit patients starting first treatment (CLL14, GLOW); Fit patients starting first treatment (CLL13, AMPLIFY); Early-stage CLL under watch and wait
- Biomarkers: del(17p) by FISH and TP53 mutation; IGHV mutational status; CLL-IPI score; Beta-2 microglobulin; Complex karyotype; Undetectable MRD at end of fixed-duration therapy; Cardiac risk factors before BTK inhibitors

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/cll-treatment-naive/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/cll-treatment-naive/#overview [3 state-of-the-art points]
- Types and stages (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/cll-treatment-naive/#what-it-is [6 subtypes]
- Symptoms and diagnosis (on the hub): How this cancer shows itself, how the diagnosis is confirmed, and the biomarkers clinicians test for. https://onco.cc/cancers/cll-treatment-naive/#finding-it [7 biomarkers]
- Treatment (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/cll-treatment-naive/#treating-it [4 settings, 3 decisions with options]
- Trials and papers (on the hub): Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/cll-treatment-naive/#evidence [24 trials, 4 key papers, 7 milestones]
- Biology and targets (on the hub): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/cll-treatment-naive/#science [3 targets, 2 pathways]
- Countries and centres (own page): Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes. https://onco.cc/cancers/cll-treatment-naive/where-you-are/
- Decisions and support (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/cll-treatment-naive/#living-with-it [18 questions, 6 red cards]
- Pipeline and open problems (own page): Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/cll-treatment-naive/coming/ [12 medicines, 22 trials, 2 ideas, 3 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/cll-treatment-naive/data/ [82 connected records]

## Standard of care

- Asymptomatic early-stage disease: Watch and wait with counts every three to twelve months; treat only on iwCLL indications. ([Flow cytometry (immunophenotyping)](https://onco.cc/terms/flow-cytometry/), [IGHV mutational status](https://onco.cc/terms/ighv-status/), [del(17p) / TP53 aberration in CLL](https://onco.cc/terms/del17p-tp53/), [Cytogenetics and FISH](https://onco.cc/technologies/cytogenetics-fish/))
- First treatment, fixed duration: Venetoclax plus obinutuzumab for 12 months (CLL14, CLL13); ibrutinib-venetoclax (GLOW, CAPTIVATE) or acalabrutinib-venetoclax with or without obinutuzumab (AMPLIFY) for fit patients. ([Venetoclax](https://onco.cc/drugs/venetoclax/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [CLL14](https://onco.cc/trials/cll14/), [CLL13 / GAIA](https://onco.cc/trials/cll13-gaia/), [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [GLOW](https://onco.cc/trials/glow/), [CAPTIVATE](https://onco.cc/trials/captivate/), [AMPLIFY](https://onco.cc/trials/amplify/), [Venetoclax + obinutuzumab (12 months)](https://onco.cc/pairings/venetoclax-plus-obinutuzumab/), [BTK inhibitor + venetoclax, fixed duration](https://onco.cc/pairings/btki-plus-venetoclax-fixed-duration/))
- First treatment, continuous: Acalabrutinib (ELEVATE-TN) or zanubrutinib (SEQUOIA) until progression, preferred for del(17p) or TP53-mutated disease; ibrutinib where the newer agents are unavailable. ([Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/), [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [ELEVATE-TN](https://onco.cc/trials/elevate-tn/), [SEQUOIA](https://onco.cc/trials/sequoia/), [Caution: ibrutinib in patients with cardiac risk](https://onco.cc/pairings/btki-ibrutinib-cardiac-caution/))
- Chemoimmunotherapy: Fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab only for IGHV-mutated disease without TP53 aberration where targeted drugs are unavailable; never for del(17p). ([Fludarabine](https://onco.cc/drugs/fludarabine/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Rituximab](https://onco.cc/drugs/rituximab/), [Bendamustine](https://onco.cc/drugs/bendamustine/), [Chlorambucil](https://onco.cc/drugs/chlorambucil/), [Caution: chemoimmunotherapy in del(17p)/TP53 CLL](https://onco.cc/pairings/cit-in-del17p-caution/))

## State of the art

- Chemoimmunotherapy has been displaced by BTK inhibitors and venetoclax-based fixed-duration regimens for almost every patient.
- One year of venetoclax-obinutuzumab keeps half of older patients progression-free at six years.
- All-oral fixed-duration doublets and MRD-guided duration are the current direction.

## Open problems

- Continuous BTK inhibitor or fixed-duration venetoclax first: no head-to-head survival data.
- Whether MRD should decide how long fixed-duration therapy lasts.
- Cardiac toxicity, cost and interactions of indefinite BTK inhibition in patients in their seventies and eighties.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia
- Wikipedia: https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia
- NCCN Guidelines: CLL/SLL: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Relapsed or refractory chronic lymphocytic leukaemia](https://onco.cc/cancers/cll-relapsed/), [Richter transformation of chronic lymphocytic leukaemia](https://onco.cc/cancers/richter-transformation-cll/)
- technologies: [BCL-2 inhibitors](https://onco.cc/technologies/bcl2-inhibitors/), [Cytogenetics and FISH](https://onco.cc/technologies/cytogenetics-fish/), [Multiparameter flow cytometry MRD](https://onco.cc/technologies/flow-cytometry-mrd/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/), [BTK (Bruton tyrosine kinase)](https://onco.cc/targets/btk/), [CD20](https://onco.cc/targets/cd20/)
- pathways: [B-cell receptor / BTK signalling (to NF-κB)](https://onco.cc/pathways/bcr-signalling/), [Intrinsic apoptosis (BCL-2 family)](https://onco.cc/pathways/apoptosis-bcl2/)
- terms: [CLL-IPI (chronic lymphocytic leukaemia prognostic index)](https://onco.cc/terms/cll-ipi/), [del(17p) / TP53 aberration in CLL](https://onco.cc/terms/del17p-tp53/), [Flow cytometry (immunophenotyping)](https://onco.cc/terms/flow-cytometry/), [IGHV mutational status](https://onco.cc/terms/ighv-status/), [TP53-mutated (p53-abnormal)](https://onco.cc/terms/tp53-mutated/), [Tumour lysis syndrome (TLS)](https://onco.cc/terms/tumor-lysis-syndrome/), [Undetectable MRD (uMRD / MRD-negative)](https://onco.cc/terms/umrd/)
- trials: [A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma](https://onco.cc/trials/nct05057494/), [A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)](https://onco.cc/trials/nct05624554/), [A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)](https://onco.cc/trials/nct05023980/), [A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia](https://onco.cc/trials/nct05963074/), [A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period](https://onco.cc/trials/nct06524375/), [A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)](https://onco.cc/trials/nct06428019/), [A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia](https://onco.cc/trials/nct07277231/), [A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia](https://onco.cc/trials/nct06637501/), [AMPLIFY](https://onco.cc/trials/amplify/), [BELLWAVE-011](https://onco.cc/trials/bellwave-011/), [CaDAnCe-304](https://onco.cc/trials/cadance-304/), [CAPTIVATE](https://onco.cc/trials/captivate/), [CELESTIAL-TNCLL](https://onco.cc/trials/celestial-tncll/), [CLL12](https://onco.cc/trials/cll12/), [CLL13 / GAIA](https://onco.cc/trials/cll13-gaia/), [CLL14](https://onco.cc/trials/cll14/), [ELEVATE-TN](https://onco.cc/trials/elevate-tn/), [Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients](https://onco.cc/trials/nct00254163/), [GLOW](https://onco.cc/trials/glow/), [ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)](https://onco.cc/trials/apex-03/), [RESONATE-2](https://onco.cc/trials/resonate-2/), [SEQUOIA](https://onco.cc/trials/sequoia/), [Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia](https://onco.cc/trials/nct04075292/), [Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He](https://onco.cc/trials/nct07509151/)
- key papers: [AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients](https://onco.cc/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/), [CLL12: ibrutinib in early-stage chronic lymphocytic leukaemia, a randomised placebo-controlled phase 3 trial](https://onco.cc/key-papers/paper-cll12-ibrutinib-early-stage-langerbeins-jco-2025/), [CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients](https://onco.cc/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/), [ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL](https://onco.cc/key-papers/paper-elevate-tn-acalabrutinib-lancet-2020/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Bendamustine](https://onco.cc/drugs/bendamustine/), [Chlorambucil](https://onco.cc/drugs/chlorambucil/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/), [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Nemtabrutinib](https://onco.cc/drugs/nemtabrutinib/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Rituximab](https://onco.cc/drugs/rituximab/), [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/), [Venetoclax](https://onco.cc/drugs/venetoclax/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- ideas: [BTK degraders to pre-empt resistance in frontline CLL](https://onco.cc/ideas/idea-btk-degrader-frontline/), [MRD-guided treatment duration in CLL](https://onco.cc/ideas/idea-mrd-guided-stop-cll/)
- pairings: [BTK inhibitor + venetoclax, fixed duration](https://onco.cc/pairings/btki-plus-venetoclax-fixed-duration/), [Caution: chemoimmunotherapy in del(17p)/TP53 CLL](https://onco.cc/pairings/cit-in-del17p-caution/), [Caution: ibrutinib in patients with cardiac risk](https://onco.cc/pairings/btki-ibrutinib-cardiac-caution/), [Venetoclax + obinutuzumab (12 months)](https://onco.cc/pairings/venetoclax-plus-obinutuzumab/)
- people: [Jan A. Burger](https://onco.cc/people/jan-burger/)
- companies: [German CLL Study Group](https://onco.cc/companies/german-cll-study-group/)

---
JSON: https://onco.cc/api/v1/entities/cll-treatment-naive.json